Striatal concentrations of vesicular monoamine transportes are identical in MPTP-sensitive (C57BL/6) and -insensitive (CD-1) mouse strains

European Journal of Pharmacology

Volumn 307, Issue 2, 1996, Pages 227-232

  Kilbourn, Michael ^a,b   Frey, Kirk ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Dihydrotetrabenazine; Methoxytetrabenazine; MPTP (1 methyl 4 phenyl 1,2,3,6 tetrahydropyridine); Vesicular monoamine transporter; VMAT2 (vesicular monoamine transporter type 2)

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CARBON 11; DIHYDROTETRABENAZINE; METHOXYTETRABENAZINE C 11; MONOAMINE TRANSPORTER; RADIOLIGAND; UNCLASSIFIED DRUG;

AMINE TRANSPORT; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BRAIN REGION; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; DRUG SENSITIVITY; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; LIGAND BINDING; MALE; MEMBRANE VESICLE; MOUSE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; STRAIN DIFFERENCE;

EID: 0030603785     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/0014-2999(96)00252-X     Document Type: Article

References (21)

1. Cohen, G. and J. Evans, Vesicular binding of 6-hydroxydopamine does not explain the resistance of dopamine nerve terminals to 6-hydroxydopa, Neurodegeneration 1, 241.
2. 11C]methoxy derivative of α-dihydrotetrabenazine: a radioligand for studying the vesicular monoamine transporter, Nucl. Med. Biol. 44, 1487.
3. + uptake into synaptic dopamine vesicles: possible involvement in MPTP neurotoxicity, Br. J. Pharmacol. 109, 411.
4. Dluzen, D.E., J.L. McDermott and B. Liu, 1996, Estrogen alters MPTP-induced neurotoxicity in female mice: effects on striatal dopamine concentrations and release. J. Neurochem. 66, 658.
5. Edwards, R.H., 1993, Neural degeneration and the transport of neurotransmitters, Ann. Neurol. 34, 638.
6. Giovanni. A., B. Sieber, R. Heikkila and P.K. Sonsalla, 1991, Correlation between the neostriatal content of the 1-methyl-4-phenylpyridinium species and the dopaminergic neurotoxicity following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration to several strains of mice, J. Pharmacol. Exp. Ther. 257, 691.
7. +) within catecholaminergic neurons, NeuroTox. 12, 285.
8. Jossan, S.S., E. Sakurai and L. Oreland, 1989, MPTP toxicity in relationship to age, dopamine uptake and MAO-B activity in two rodent species, Pharmacol. Toxicol. 64, 314.
9. Kelly, R.B., 1993, Storage and release of neurotransmitters, Neuron 10, 43.
10. Kilbourn, M.R., 1994, PET radioligands for vesicular neurotransmitter transporters, Med. Chem. Res. 5, 113.
11. 18F]GBR 13119, a dopamine uptake inhibitor, in CD-1 and C57BL/6 mice, Eur. J. Pharmacol. 166, 331.
12. Muthane, U., K.A. Ramsay, H. Jiang, V. Jackson-Lewis, D. Donaldson, S. Fernaldo, M. Ferreira and S. Predborski, 1994, Differences in nigral neuron number and sensitivity to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57/b1 and CD-1 mice, Exp. Neurol. 126, 195.
13. Reinhard, J.F., Jr., A.J. Daniels and O.H. Viveros, 1988, Potentiation by reserpine and tetrabenazine of brain cetecholamine depletions by MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) in the mouse: evidence for subcellular sequestration as basis for cellular resistance to the toxicant, Neurosci. Lett. 90, 349.
14. Sanghera, M.K., F. Crespi, K.F. Martin, D.J. Heal, W.R. Buckett and C.D. Marsden, 1990, Biochemical and in vivo voltammetric evidence for differences in striatal dopamine levels in inbred strains of mice, Neuroscience 39, 649.
15. Schuldiner, S., A. Shirvan and M. Linial, 1995, Vesicular neurotransmitter transporters: from bacteria to humans, Physiol. Rev. 75, 369.
16. Takada, M., T. Sugimoto and T. Hattori, 1993, MPTP neurotoxicity to cerebellar Purkinje cells in mice, Neurosci. Lett. 150, 49.
17. Unzeta, M., S. Baron, V. Perez, S. Ambrosio and N. Maly, 1994. Sex-related effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment may be related to differences in monoamine oxidase B, Neurosci. Lett. 176, 235.
18. Vander Borght, T.M., M.R. Kilbourn, T.J. Desmond, D.E. Kuhl and K.A, Frey, 1995a, The vesicular monoamine transporter is not regulated by dopaminergic drug treatments, Eur. J. Pharmacol. 294, 577.
19. 3H]Methoxytetrabenazine: a high specific activity ligand for estimating monoaminergic neuronal integrity, Neuroscience 68, 955.
20. Zigmond, M.J. and E.M. Stricker, 1989, Animal models of parkinsonism using selective neurotoxins: clinical and basic implications, Int. Rev. Neurobiol. 31, 1.
21. + neurotoxicity and delays its elimination from the striatum, Brain Res. 501, 11.